Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person UniProt:P11182 DBT

Class:IdReferenceGeneProduct:60856
_chainChangeLogtransit peptide:1-61 added on Sat February 7 2015;chain:62-482 added on Sat February 7 2015
_displayNameUniProt:P11182 DBT
_timestamp2026-02-20 22:46:49
chaintransit peptide:1-61
chain:62-482
checksumA6CE6E8D532E10FA
commentFUNCTION The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of three enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3). Within this complex, the catalytic function of this enzyme is to accept, and to transfer to coenzyme A, acyl groups that are generated by the branched-chain alpha-keto acid decarboxylase component.CATALYTIC ACTIVITY N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] + 2-methylpropanoyl-CoA = N(6)-[(R)-S(8)-2-methylpropanoyldihydrolipoyl]-L-lysyl-[protein] + CoACATALYTIC ACTIVITY N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] + 3-methylbutanoyl-CoA = N(6)-[(R)-S(8)-3-methylbutanoyldihydrolipoyl]-L-lysyl-[protein] + CoACATALYTIC ACTIVITY (2S)-2-methylbutanoyl-CoA + N(6)-[(R)-dihydrolipoyl]-L-lysyl-[protein] = N(6)-{(R)-S(8)-[(2S)-2-methylbutanoyl]dihydrolipoyl}-L-lysyl-[protein] + CoACOFACTOR Binds 1 lipoyl cofactor covalently.SUBUNIT Forms a 24-polypeptide structural core with octahedral symmetry that represents the E2 component of the branched-chain alpha-ketoacid dehydrogenase (BCKDH) complex. The BCKDH complex is composed of three major building blocks E1, E2 and E3. It is organized around E2, a 24-meric cubic core composed of DBT, to which are associated 6 to 12 copies of E1, and approximately 6 copies of the dehydrogenase E3, a DLD dimer (By similarity) (PubMed:22291014). Interacts with PPM1K with a 24:1 stoichiometry; the N-terminal region (residues 49-61) of PPM1K and C-terminal linker of the lipoyl domain of DBT/E2 (residues 145-160) are critical for this interaction whereas the lipoyl prosthetic group is dispensable. This interaction requires colocalization in mitochondria (PubMed:19411760, PubMed:22291014, PubMed:22589535). PPM1K competes with BCKDK for binding to DBT; this interaction is modulated by branched-chain alpha-keto acids (BCKAs). At steady state, BCKDH holoenzyme preferentially binds BCKDK and BCKDHA is phosphorylated. In response to high levels of BCKAs, BCKDK is replaced by PPM1K leading to BCKDHA dephosphorylation (PubMed:22589535, PubMed:37558654).INTERACTION Patients with primary biliary cirrhosis (PBC) show autoantibodies against the E2 component of branched-chain alpha-keto acid dehydrogenase complex. PBC is a chronic, progressive cholestatic liver disease characterized by the presence of antimitochondrial autoantibodies in patients serum. It manifests with inflammatory obliteration of intra-hepatic bile duct, leading to liver cell damage and cirrhosis.DISEASE The disease is caused by variants affecting the gene represented in this entry.SIMILARITY Belongs to the 2-oxoacid dehydrogenase family.SEQUENCE CAUTION Truncated N-terminus.SEQUENCE CAUTION Truncated N-terminus.
descriptionrecommendedName: fullName evidence="28"Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial ecNumber evidence="1"2.3.1.168 alternativeName: fullName evidence="24"52 kDa mitochondrial autoantigen of primary biliary cirrhosis alternativeName: fullName evidence="26 27"Branched chain 2-oxo-acid dehydrogenase complex component E2 shortName evidence="26 27"BCOADC-E2 alternativeName: Branched-chain alpha-keto acid dehydrogenase complex component E2 shortName: BCKAD-E2 shortName: BCKADE2 shortName evidence="25"BCKDH-E2 alternativeName: Dihydrolipoamide acetyltransferase component of branched-chain alpha-keto acid dehydrogenase complex alternativeName: Dihydrolipoamide branched chain transacylase alternativeName: Dihydrolipoyllysine-residue (2-methylpropanoyl)transferase
geneNameDBT
BCATE2
BCKDHE2
identifierP11182
isSequenceChangedFALSE
keyword3D-structure
Acetylation
Acyltransferase
Direct protein sequencing
Disease variant
Lipoyl
Maple syrup urine disease
Mitochondrion
Phosphoprotein
Proteomics identification
Reference proteome
Transferase
Transit peptide
modified[InstanceEdit:9836292] Weiser, Joel, 2023-05-25
[InstanceEdit:9852000] Weiser, Joel, 2023-11-03
[InstanceEdit:9862192] Weiser, Joel, 2024-02-26
[InstanceEdit:9917590] Weiser, Joel, 2024-08-09
[InstanceEdit:9926675] Weiser, Joel, 2024-11-03
[InstanceEdit:9939033] Weiser, Joel, 2025-02-21
[InstanceEdit:9983091] Weiser, Joel, 2026-02-20
nameDBT
referenceDatabase[ReferenceDatabase:2] UniProt
referenceGene[ReferenceDNASequence:8995010] ENSEMBL:ENSG00000137992 DBT [Homo sapiens]
secondaryIdentifierODB2_HUMAN
B2R811
Q5VVL8
sequenceLength482
species[Species:48887] Homo sapiens
(referenceEntity)[EntityWithAccessionedSequence:70017] Lipo-K105-DBT [mitochondrial matrix] [Homo sapiens]
[EntityWithAccessionedSequence:6792584] DBT [mitochondrial matrix] [Homo sapiens]
[EntityWithAccessionedSequence:9714663] DBT [cytosol] [Homo sapiens]
[EntityWithAccessionedSequence:9859144] Isovaleryl-lipoH2-K105-DBT [mitochondrial matrix] [Homo sapiens]
[EntityWithAccessionedSequence:9859145] 2-Methylbutyryl-lipoH2-K105-DBT [mitochondrial matrix] [Homo sapiens]
[EntityWithAccessionedSequence:9859151] Isobutyryl-lipoH2-K105-DBT [mitochondrial matrix] [Homo sapiens]
[EntityWithAccessionedSequence:9859167] LipoH2-K105-DBT [mitochondrial matrix] [Homo sapiens]
[EntityWithAccessionedSequence:9865036] S399C Lipo-K105-DBT [mitochondrial matrix] [Homo sapiens]
[EntityWithAccessionedSequence:9865046] P276C Lipo-K105-DBT [mitochondrial matrix] [Homo sapiens]
[EntityWithAccessionedSequence:9865051] K313_Y338del Lipo-K105-DBT [mitochondrial matrix] [Homo sapiens]
List all 11 refering instances
(referenceSequence)[ModifiedResidue:508256] N6-lipoyl-L-lysine at 105
[GroupModifiedResidue:9859141] N6-lipoyl-L-lysine ((R)-N6-(S8-isobutyryldihydrolipoyl)-L-lysine residue) at 105
[GroupModifiedResidue:9859142] N6-lipoyl-L-lysine ((R)-N6-(S8-2-methylbutyryldihydrolipoyl)-L-lysine residue) at 105
[GroupModifiedResidue:9859146] N6-lipoyl-L-lysine ((R)-N6-(S8-isovaleryldihydrolipoyl)-L-lysine residue) at 105
[GroupModifiedResidue:9859166] N6-lipoyl-L-lysine ((R)-N6-dihydrolipoyl-L-lysine residue) at 105
[ReplacedResidue:9865012] L-isoleucine 98 replaced with L-methionine
[ReplacedResidue:9865013] L-phenylalanine 276 replaced with L-cysteine
[ReplacedResidue:9865022] L-serine 399 replaced with L-cysteine
[FragmentDeletionModification:9865027] Deletion of residues 313 to 338
[Change default viewing format]
No pathways have been reviewed or authored by UniProt:P11182 DBT (60856)